|  |  |  |  |
| --- | --- | --- | --- |
| **Attrition analyses showing baseline values of participants attending and not attending follow-up (n=277)** | | | |
|  |  |  |  |
|  | **Attending follow-up (n=204)** | **Lost to Follow-up (n=73)** | **p** |
| **Female, n (%)** | 103 ( 50.5) | 33 (45.2) | 0.44a |
| **Age, mean (SD)** | 25 (4.1) | 26 (4.2) | 0.30b |
|  |  |  |  |
| **Diagnosis of harmful or dependency syndrome, n (%)** | 47 (23) | 19 (26) | 0.61b |
|  |  |  |  |
| **Psychotic symptoms, mean (SD)** | 2.0 (1.2) | 2.4 (1.2) | 0.017a |
| **Disorganized symptoms, mean (SD)** | 0.42 (0.55) | 0.58 (0.63) | 0.036a |
| **Negative symptoms, mean (SD)** | 1.9 (0.97) | 2.2 (0.88) | 0.029a |
|  |  |  |  |
| **Functional level, PSP, mean (SD)** | 48 (13) | 45 (11) | 0.062a |
|  |  |  |  |
| **Schizophrenia, n (%)** | 196 (96) | 67 (92) |  |
| **Delusional Disorder, n (%)** | 6 (2.9) | 2 (2.7) |  |
| **Brief and transient psychotic disorder, n (%)** | 1 (0.5) | 0 (0) |  |
| **Schizoaffective disorders, n (%)** | 0 (0) | 4 (5.5) |  |
| **Unspecified nonorganic psychosis, n (%)** | 1 (0.5) | 0 (0) | 0.017b \* |
|  |  |  |  |
| **Chlorpromazine equivalents mg, mean (SD)** | 459 (276) | 508 (396) | 0.24a |
| **Chlorpromazine equivalents mg, median (range)** | 400 (0.6-1540) | 400 (24-1800) | 0.79c |
|  |  |  |  |
| Abbreviation: PSP – Personal and Social Performance scale. a: ANOVA, b: chi-square, c: Mann-Whitney U test. \*The significant difference is explained by the 4 participants with a schizoaffective disorder all not attending follow-up. | | | |